【第1日目】2018年6月29日（金） 第63回日本透析 …

1 1 2018 6 29 63 -1 1 A 2 B 3 C 4 5 6 7 8 9 3 10 11 1 12 3 13 4 401+402 14 501 15 502 16 504+505 17 A 18 B 19 22A 20 33A 21 2 22 5 23 16 24 - SSPESSLGIKSLS0 MSELBSYMSY - 78910111213 ELA22 1 -12 78910111920131415161718 21 4 20 ( ) 15161718191420 B15B11 LS-3 ( )KS-01 MBD LS-6 ( )LS-2 ( )LS-8 ( )LS-9 ( )LS-10 ( )LS-11( ) LS-12 ( )LS-13 ( )LS-14 ( )LS-15 ( )LS-16( ) LS-17 ( )LS-7 ( )LS-1 ( )LS-4 ( )KS-02 KS-04 SS-2 ( / ( )SS-1 ( GI-01 JSDT SY-02 SY-04 SL-3 ELB-04 : ELB-05 ELB-07 ELB-02 reject : ELB-01 ELA-02-1 WS-05 AKI WS-02 WS-01 upto date WS-04 WS-07 WS-03 Drug in CKD (.)))

2 WS-06 QOL ELB-03 PL-1 SL-1 GI-02 SY-03 KDIGO guideline CKD-MBD KDIGO CKD-MBD Guideline Update and Clinical Practice in Japan SY-01 HDF GI-04 GI-03 SS-3 ( ) NS / / / / / O-HDF O-HDF O-HDF PTA3 PTA O-HDFI-HDF O-HDFI-HDF O-HDFI-HDF CKD-MBD/ / CKD-MBD/ / CKD-MBD/ / CKD-MBD/ / CKD-MBD/ / CKD-MBD/ / AKI AKI PD PD Eps

3 Hb RCT WS-08 ELB-08 ELB-06 ES-1 ( ) ( ) GI-13-2 SY Current status and countermeasures of Virus infection in dialysis patients MunekazuRyuzakiNobuhito Hirawa ELA-01-1 GI-13-1 FreeCommunication 1 YoshihikoKannoYugo ShibagakiKS-03 PTA O-HDFI-HDF SL-2 LS-55( ) LS-5 ( ) 2018 6 30 63 -1 1 A 2 B 3 C 4 5 6 7 8 9 3 10 11 1 12 3 13 4 401+402 14 501 15 502 16 504+505 17 A 18 B 19 22A 20 33A 21 2 22 5 23 16 24 - SYMSYMSSSP0 SLGIKSLS211920ES1314151617181 B115 ELBELA12 7891011 7892110111213142016 - 4 20 ( ) 171819 1 22 5 -B1LS-18 ( ) LS-22 ( )LS-23 ( )LS-24 ( )LS-25 ( )LS-20 ( )LS-21 ( )LS-27 ( )LS-28( )JIMROLS-29 ( )LS-30 ( )LS-31( ) / ( )LS-32 ( )LS-33 ( )/ ( )LSLS-35 ( )/( )

4 / LS-36 ( )LS-37EA ( )/ ( ) LS-38 ( )LS-39 JCR ( )/ ( )LS-19 ( ) ( )KS-06 KS-07 Total Management SS-4 ( ELB-09 ELB-11 up to date MSY 50 SY-06 ELB-13 ELB-14 ELA-03-1 ELA-05-1 Iron metabolism in CKD patients Guenter Weiss ELA-06-1 AHED WS-09 SL-4 30 WS-17 ELB-15 I-HDF ELB-12 WS-11 WS-12 CKD-MBD calcimimetics SY-05 SY-07 WS-16)

5 GI-05 2017 Year in review WS-13 GI-06 1-2 TSUBASA PROJECT KS-05 SharedDecisionMaking KS-08 CKD LS-34 ( )SS-5( QOL / VA CHDF PD PD PD LS-26 ( )GI-07 WS-14 WS-10 CKD CKD-MBD/ PTX,PEIT )CKD-MBD/FGF-23 D PTH CKD-MBD/ / CKD-MBD/ CKD-MBD/ / / CVD/ PAD/ CVD/ K CARTELB-10 2.

6 ES-2 ( ) SY-08 GI-13-3 Nutritionalmanagement ingiaiysis patients YoshitakaIsakaGI-13-4 The Dialysis History and Status of 2018 in Non-Western Countries YusukeTsukamoto Toru HyodoO-HDF O-HDF O-HDF CKD-MBD/ / CKD-MBD/ GCAP LCAP PD HD HDF ELA-07-1 MRI ELA-04-1 GI-13-5 FreeCommunication 2 YukioYuzawa Masanori Abe / CKD-MBD/ / WS-15 GI-08 / 2018 7 1 63 -1 1 A 2 B 3 C 4 5 6 7 8 9 3 10 11 1 12 3 13 4 401+402 14 501 15 502 16

7 504+505 17 A 18 B 19 22A 20 33A 21 2 22 5 23 16 24 - 81120 PESMS1314129101915161718 ELBELASYMSYSSSLGIKSLS0 78910111213142015 B1 B116 1 -5 - 1 22 2121 4 20 ( ) 171819 7 LS-43 ( )LS-44 ( )LS-41 ( )LS-42 ( )LS-45 ( )LS-46 ( )LS-47 ( )LS-48 ( )LS-49 ( )LS-50 ( )LS-51( ) LS-53 ( )/ ( )LS-54( ) LS-40 ( )GI-12 SY-10 SY-11 CKD ELB-16 ELB-20 ELA-08-1 CKD-MBD WS-18 Vascular WS-23 WS-26 : SL-7 ELB-19 WS-24 VA : ELB-17 ELB-18 WS-22.

8 WS-21 -FGF23-Klotho axis GI-11 WS-20 KS-09 DOPPS SY-09 PDOPPS HidekiKawanishiBruce RobinsonSY-12 QOL SL-8 Volker WS-25 KS-10 LS-52 ( )/ ( ) / / / PD QOL PD ESA ANCA / / / / / / CVD/ CVD/ CVD/ / PAD PAD PD PD PD PD PD O-HDF O-HDF AKI GI-09 WS-19 CVD/ / / / MS-1 ( )

9 PD GI-10 ! ELB-21 CKD-MBD/ / PE( ) SL-5 SL-6 W SL-9 Subhir K Bowry